FOLH1 and prostate carcinoma: SNAs functionalized with prostate tumor-associated antigens (PSMA, or PAP) resulted in tumor inhibition upon immunization with HM SNAs in both RM1-PSMA and TRAMP-C2 (PAP) prostate cancer models.